CGIX News and Press, Cancer Genetics Inc. From 07/15/19

Sale of BioPharma business to Interpace Diagnostics Group, Inc. Clinical services business acquired by siParadigm Diagnostic Informatics Significantly reduces its debt burden and will continue to operate its Discovery Business RUTHERFORD, N.J., July 15, 2019 (GLOBE NEWSWIRE) --...

Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain l...

RALEIGH, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment of Ed Sitar as its Chief Financial Off...

Cancer Genetics (NASDAQ: CGIX ): Q1 GAAP EPS of -$0.09. More news on: Cancer Genetics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RUTHERFORD, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data solutions, today announced financial and operating results for the first ...

Cancer Genetics (NASDAQ: CGIX ): Q4 GAAP EPS of -$0.14 beats by $0.02 . More news on: Cancer Genetics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data solutions, today announced financial and operating results for the four...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced public of...

Cancer Genetics ( CGIX ) priced public offering of 15.21M common shares at $0.23/share for gross proceeds of ~$3.5M. More news on: Cancer Genetics, Inc., Healthcare stocks news, Read more ...